{"id":"https://openalex.org/W3095453422","doi":"https://doi.org/10.1182/blood-2020-136134","title":"Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?","display_name":"Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3095453422","doi":"https://doi.org/10.1182/blood-2020-136134","mag":"3095453422"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-136134","doi":"https://doi.org/10.1182/blood-2020-136134","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-136134","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082291642","display_name":"Jean\u2010Marie Michot","orcid":"https://orcid.org/0000-0003-3482-3331","observed_orcids":["https://orcid.org/0000-0003-3482-3331"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jean-Marie Michot","raw_affiliation_strings":["Gustave Roussy Cancer Campus, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy Cancer Campus, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043373936","display_name":"Val\u00e9rie Camara\u2010Clayette","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Val\u00e9rie Camara-Clayette","raw_affiliation_strings":["INSTITUT GUSTAVE ROUSSY, Villejuif, FRA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"INSTITUT GUSTAVE ROUSSY, Villejuif, FRA","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054440976","display_name":"Cyril Quivoron","orcid":"https://orcid.org/0000-0002-9871-0187","observed_orcids":["https://orcid.org/0000-0002-9871-0187"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I277688954","display_name":"Universit\u00e9 Paris-Saclay","ror":"https://ror.org/03xjwb503","country_code":"FR","type":"education","lineage":["https://openalex.org/I277688954"]},{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Cyril Quivoron","raw_affiliation_strings":["Gustave Roussy, INSERM U1170, Universit\u00e9 Paris-Saclay, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy, INSERM U1170, Universit\u00e9 Paris-Saclay, Villejuif, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I277688954","https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108831713","display_name":"Alina Danu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Alina Danu","raw_affiliation_strings":["Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104830716","display_name":"Julien Lazarovici","orcid":"https://orcid.org/0009-0000-3496-7445","observed_orcids":["https://orcid.org/0009-0000-3496-7445"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Julien Lazarovici","raw_affiliation_strings":["Department of hematology, Gustave Roussy Cancer Campus Grand Paris, Villejuif CEDEX, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of hematology, Gustave Roussy Cancer Campus Grand Paris, Villejuif CEDEX, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100643218","display_name":"David Ghez","orcid":"https://orcid.org/0000-0002-2240-2065","observed_orcids":["https://orcid.org/0000-0002-2240-2065"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"David Ghez","raw_affiliation_strings":["Service d'H\u00e9matologie, D\u00e9partement de M\u00e9decine, Gustave Roussy Cancer Campus, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Service d'H\u00e9matologie, D\u00e9partement de M\u00e9decine, Gustave Roussy Cancer Campus, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007732660","display_name":"Julien Rossignol","orcid":"https://orcid.org/0000-0003-3052-1424","observed_orcids":["https://orcid.org/0000-0003-3052-1424"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]},{"id":"https://openalex.org/I4405269973","display_name":"Fondation Gustave Roussy","ror":"https://ror.org/05rfnt234","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4405269973"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Julien Rossignol","raw_affiliation_strings":["Hematology, Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802","https://openalex.org/I4405269973"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028963681","display_name":"Capucine Baldini","orcid":"https://orcid.org/0000-0002-0604-7614","observed_orcids":["https://orcid.org/0000-0002-0604-7614","https://orcid.org/0000-0002-3332-0225"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Capucine Baldini","raw_affiliation_strings":["Gustave Roussy Cancer Campus, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy Cancer Campus, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080474091","display_name":"Patricia Mart\u00edn-Romano","orcid":"https://orcid.org/0000-0002-3923-5160","observed_orcids":["https://orcid.org/0000-0002-3923-5160"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Patricia Martin-Romano","raw_affiliation_strings":["DITEP, Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DITEP, Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044269394","display_name":"Cl\u00e9mentine Sarkozy","orcid":"https://orcid.org/0000-0002-1942-9304","observed_orcids":["https://orcid.org/0000-0002-1942-9304"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Clementine Sarkozy","raw_affiliation_strings":["DITEP, Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DITEP, Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034376000","display_name":"Andr\u00e9a Varga","orcid":"https://orcid.org/0000-0002-1314-384X","observed_orcids":["https://orcid.org/0000-0002-1314-384X"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Andrea Varga","raw_affiliation_strings":["Gustave Roussy Cancer Campus, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy Cancer Campus, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071570443","display_name":"H\u00e9l\u00e8ne Lecourt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Helene Lecourt","raw_affiliation_strings":["Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046799085","display_name":"V\u00e9ronique Verg\u00e9","orcid":"https://orcid.org/0000-0002-3233-5978","observed_orcids":["https://orcid.org/0000-0002-3233-5978"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Veronique Verg\u00e9","raw_affiliation_strings":["Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005029412","display_name":"Sophie Cotteret","orcid":"https://orcid.org/0000-0001-5598-0112","observed_orcids":["https://orcid.org/0000-0001-5598-0112"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Sophie Cotteret","raw_affiliation_strings":["Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047997030","display_name":"Peggy Dartigues","orcid":"https://orcid.org/0009-0002-8383-3050","observed_orcids":["https://orcid.org/0009-0002-8383-3050"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Peggy Dartigues-Cuill\u00e8res","raw_affiliation_strings":["Pathology Department, Institut Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pathology Department, Institut Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090082356","display_name":"Christophe Massard","orcid":"https://orcid.org/0000-0001-5505-0564","observed_orcids":["https://orcid.org/0000-0001-5505-0564"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Christophe Massard","raw_affiliation_strings":["Gustave Roussy Cancer Campus, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy Cancer Campus, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032462496","display_name":"Vincent Ribrag","orcid":"https://orcid.org/0000-0002-5221-353X","observed_orcids":["https://orcid.org/0000-0002-5221-353X"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Vincent Ribrag","raw_affiliation_strings":["Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.21450577,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"136","issue":"Supplement 1","first_page":"18","last_page":"19"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00419999985024333,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9509999752044678},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.9419999718666077},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.7710000276565552},{"id":"https://openalex.org/keywords/molecular-characterization","display_name":"molecular characterization","score":0.7160000205039978},{"id":"https://openalex.org/keywords/actionable-molecular-targets","display_name":"actionable molecular targets","score":0.5920000076293945},{"id":"https://openalex.org/keywords/germline-mutations","display_name":"germline mutations","score":0.628000020980835},{"id":"https://openalex.org/keywords/myd88-mutation","display_name":"MYD88 mutation","score":0.7329999804496765},{"id":"https://openalex.org/keywords/ezh2-mutation","display_name":"EZH2 mutation","score":0.8569999933242798},{"id":"https://openalex.org/keywords/cd79b-mutation","display_name":"CD79B mutation","score":0.8960000276565552},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.7009999752044678},{"id":"https://openalex.org/keywords/braf-inhibitors","display_name":"BRAF inhibitors","score":0.550000011920929},{"id":"https://openalex.org/keywords/genomic-heterogeneity","display_name":"genomic heterogeneity","score":0.45500001311302185},{"id":"https://openalex.org/keywords/precision-medicine","display_name":"precision medicine","score":0.6679999828338623},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.3919999897480011},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.5540000200271606}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6714223623275757},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6698076725006104},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5805366635322571},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5512213110923767},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.495778888463974},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.43347859382629395},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4296109676361084},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3929579555988312},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.14138036966323853},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-136134","doi":"https://doi.org/10.1182/blood-2020-136134","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-136134","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3093107738","https://openalex.org/W2906999587","https://openalex.org/W3096195062","https://openalex.org/W3173840596","https://openalex.org/W3093085465","https://openalex.org/W4379981845","https://openalex.org/W4226140559","https://openalex.org/W4385226545","https://openalex.org/W2891325984","https://openalex.org/W2623183666"],"abstract_inverted_index":{"Background:":[0],"Early":[1],"drug":[2],"development":[3],"is":[4],"associated":[5,411],"with":[6,14,35,63,76,193,238,250,305,310,314,325,340,346,349,356,359,412,417,430,433,609],"a":[7,103,311,326,360,580,603],"high":[8],"rate":[9],"of":[10,51,106,113,140,150,166,182,222,266,285,474,479,488,554,576,638,691,728,817,851,865,878,894,909,922,937,950,964,980,993,1009],"failure":[11],"in":[12,61,68,80,234,246,260,271,296,320,333,366,383,405,415,495,805,842],"patients":[13,34,309,416,429,439,498,504],"relapsed":[15,523],"or":[16,172,524,640,693,730,819,853,867,880,896,911,924,939,952,966,982,995,1011],"refractory":[17,525],"diffuse":[18,526],"large":[19,527],"B-cell":[20,528],"lymphoma":[21],"(R/R":[22],"DLBLC),":[23],"partly":[24],"due":[25],"to":[26,40,42,118,133,189,427,437,441,443,458],"genomic":[27,114,460],"heterogeneity.":[28],"Precision":[29],"medicine":[30,435],"aims":[31],"at":[32,124,486],"identifying":[33],"cancer":[36,465],"who":[37],"are":[38,509],"likely":[39,440],"respond":[41,442],"targeted":[43,59,97,119,283,444],"therapies.":[44,445],"Here":[45],"we":[46],"assessed":[47,123],"the":[48,125,134,164,267,286,468,571,574,577,587],"clinical":[49,71,178,199,264,408],"impact":[50],"characterizing":[52],"actionable":[53,169],"and":[54,57,87,116,177,180,218,236,248,253,274,329,368,373,385,390,492,501,583,602],"molecular":[55,141,170,421,475],"targets":[56,463],"matching":[58],"therapy":[60,120,224],"pts":[62,183,192,231,242,256,268,288,298,300,335,337,345,387],"R/R":[64,77,194,418,431,489,521],"DLBCL":[65,78,195,432,490],"prior":[66,220],"enrollment":[67],"early":[69,198,406],"phase":[70,407],"trials":[72,409],"(epCT).":[73],"Methods:":[74],"Pts":[75,153],"enrolled":[79,233,245,259],"epCT,":[81],"provided":[82],"paired":[83],"samples":[84,93,205],"including":[85],"germline":[86,204],"fresh":[88],"tumor":[89,202,422,493],"tissue":[90],"sample.":[91],"Paired":[92],"were":[94,121,154,184,232,244,257,269,290,371,388,593,598],"analyzed":[95],"by":[96,207,586,600,658,703,715],"next":[98],"generation":[99],"sequencing":[100],"(NGS)":[101],"using":[102],"customized":[104],"panel":[105],"44":[107],"genes":[108],"(Ion":[109],"Torrent).":[110],"Clinical":[111,138,472],"actionability":[112],"alterations":[115,461],"orientation":[117,402],"prospectively":[122],"Hematological":[126],"Tumor":[127,176],"Board":[128,637,690,727,816,850,864,877,893,908,921,936,949,963,979,992,1008],"from":[129,579],"our":[130],"Institution":[131],"according":[132],"ESMO":[135,469],"Scale":[136,470],"for":[137,197,464,471],"Actionability":[139,473],"Targets":[142,476],"(ESCAT)":[143],"tiers":[144],"(ESCAT":[145],"scale;":[146],"J.":[147],"Mateo,":[148],"Annals":[149,478],"Oncology,":[151],"2018[1]).":[152],"classified":[155],"as":[156,292,462],"molecularly":[157,496],"matched":[158,174,497,503],"(MM)":[159],"i.e.":[160],"treated":[161,237,249,304,313,324,339,348,358],"based":[162],"on":[163,280,634,687,724,813,827,847,861,874,890,905,918,933,946,960,976,989,1005],"presence":[165],"an":[167,635,688,725,814,848,862,875,891,906,919,934,947,961,977,990,1006],"ESCAT":[168,281],"abnormality,":[171],"non-molecularly":[173,502],"(no-MM).":[175],"characteristics":[179,265,485],"outcome":[181],"collected.":[185],"Results:":[186],"From":[187],"2013":[188],"2020,":[190],"90":[191],"screened":[196],"trial":[200],"had":[201],"&":[203,830],"sequenced":[206],"NGS.":[208],"The":[209,262,595],"mean":[210],"age":[211],"was":[212,225,410,584,607],"62":[213],"years":[214,532],"old":[215],"(range,":[216],"23-83)":[217],"median":[219],"lines":[221],"systemic":[223],"2":[226,344],"(range":[227],"1-9).":[228],"Sixteen":[229],"(18%)":[230],"epCT":[235,247],"MO":[239],"drugs,":[240,252],"43":[241],"(48%)":[243],"no-MM":[251,275,369,386],"31":[254],"(34%)":[255],"not":[258],"epCT.":[261],"main":[263],"similar":[270],"both":[272],"MM":[273,289,367,384],"groups":[276,578],"(table":[277],"1).":[278,399],"Based":[279],"scale,":[282],"therapies":[284],"16":[287],"distributed":[291],"\"investigational-level\"":[293],"tier":[294,318,331],"II":[295],"6":[297],"(3":[299],"EZH2":[301,306],"mutant":[302],"[m]":[303],"inhibitors;":[307],"3":[308],"CD79Bm":[312],"BTK":[315],"inhibitors);":[316],"\"hypothetical-level\"":[317,330],"III":[319],"1":[321,354],"pt":[322,355],"BRAFm":[323],"BRAF":[327],"inhibitor;":[328],"IV":[332],"9":[334],"(6":[336],"MYD88m":[338],"cereblon":[341],"modulator":[342],"drugs;":[343,353],"BCL7Am/ARID1Am":[347],"investigational":[350],"epigenetic":[351],"modifier":[352],"MYCm":[357],"PI3K":[361],"inhibitor).":[362],"Median":[363,380],"progression-free":[364],"survival":[365,382],"pts,":[370],"3.3":[372],"1.7":[374],"months,":[375,392],"respectively":[376,393],"(p=0.0092;":[377],"HR=0.47":[378],"[CI95:0.27-0.83]).":[379],"overall":[381],"20.0":[389],"6.7":[391],"(p=0.0238;":[394],"HR=0.49":[395],"[CI95:":[396],"0.26-0.91])":[397],"(figure":[398],"Conclusions:":[400],"Molecular":[401],"before":[403],"inclusion":[404],"better":[413],"outcomes":[414],"DLBCL.":[419],"A":[420,456],"profile":[423],"could":[424],"be":[425],"useful":[426],"manage":[428],"precision":[434,466],"helping":[436],"identify":[438],"Reference.":[446],"1-":[447],"Mateo":[448],"J,":[449],"Chakravarty":[450],"D,":[451],"Dienstmann":[452],"R":[453],"et":[454],"al.":[455],"framework":[457],"rank":[459],"medicine:":[467],"(ESCAT).":[477],"Oncology":[480,540],"2018;":[481],"29(9):1895-1902.":[482],"Table":[483],"1.Patient's":[484],"time":[487],"relapse":[491],"sample":[494],"(MM":[499],"group)":[500],"(no-MM":[505],"group).":[506],"Data":[507],"presented":[508],"n":[510],"(%)":[511],"unless":[512],"otherwise":[513],"stated.":[514],"MM=":[515],"Molecularly":[516],"matched.":[517,520],"no-MM=":[518],"Non-molecularly":[519],"DLBCL=":[522],"lymphoma.":[529,545],"y.o.":[530],"=":[531],"old.":[533],"mo.=":[534],"months.":[535],"ECOG":[536],"PS=":[537],"Eastern":[538],"Cooperative":[539],"Group":[541],"performance":[542],"status.":[543],"NHL=non-Hodgkin":[544],"ASCT=":[546],"Autostem":[547],"cell":[548],"transplantation.":[549],"IHC=":[550],"Immunohistochemistry.":[551],"COO=":[552],"Cell":[553],"origin.":[555],"GC=":[556],"Germinal":[557],"center.":[558],"ABC=":[559],"Activated":[560],"B-cell.":[561],"NA=":[562],"Not":[563],"available.":[564],"LDH=":[565],"Lactate":[566],"deshydrogenase.":[567],"*the":[568],"p-value":[569],"indicates":[570],"comparison":[572],"between":[573],"proportions":[575],"contingency":[581],"table,":[582],"calculated":[585,599],"exact":[588],"Fisher":[589],"test.":[590],"All":[591],"tests":[592],"non-parametric.":[594],"p":[596],"values":[597,610],"two-tailed":[601],"95%":[604],"confidence":[605],"interval":[606],"used,":[608],"less":[611],"than":[612],"0.005":[613],"considered":[614],"being":[615],"significantly":[616],"different.":[617],"Disclosures":[618],"Michot:":[619],"Argen-x:":[620],"Research":[621,624,627,630,643,646,650,664,667,670,673,676,679,682,735,738,741,744,748,752,755,792,795,808,823,856],"Funding;":[622,625,628,631,644,647,651,665,668,671,674,677,680,683,736,739,742,745,749,753,756,793,809,824,857],"Eos:":[623],"Exelixis:":[626],"Amgen:":[629],"Astex:":[632],"Membership":[633,686,723,812,846,860,873,889,904,917,932,945,959,975,988,1004],"entity's":[636,689,726,815,849,863,876,892,907,920,935,948,962,978,991,1007],"Directors":[639,692,729,818,852,866,879,895,910,923,938,951,965,981,994,1010],"advisory":[641,694,731,820,854,868,881,897,912,925,940,953,967,983,996,1012],"committees,":[642,732,855,968,997],"Eisai:":[645,899],"Daiichi":[648,779],"Sankyo:":[649],"AstraZeneca:":[652,930],"Other:":[653,698,710,760,969,998],"TRAVEL,":[654,699,711],"ACCOMMODATIONS,":[655,700,712],"EXPENSES":[656,701,713],"(paid":[657,702,714],"any":[659,704,716],"for-profit":[660,705,717],"health":[661,706,718],"care":[662,707,719],"company),":[663],"Lysarc:":[666],"Lilly:":[669],"Kyowa:":[672],"Genentech:":[675],"Forma:":[678],"Agios:":[681],"AZD:":[684,883],"Honoraria,":[685,759,845,859,872,884,888,903,916,931,944,958,987,1003],"committees;":[695,821,869,882,898,913,926,941,954,984],"Mundi":[696],"Pharma:":[697],"company);":[708,720],"Celgene:":[709],"Bristol-Myers":[721],"Squibb:":[722],"Other;":[733,885],"Xencor:":[734],"Sanofi:":[737],"Roche:":[740,957],"Medimmune:":[743],"Lytix":[746],"Biopharma:":[747],"Janssen:":[750],"Other,":[751],"Debiopharm:":[754],"Gustave":[757,833],"Roussy:":[758,834],"Abbvie,":[761],"Aduro,":[762],"Agios,":[763],"Amgen,":[764],"Argen-x,":[765],"Astex,":[766],"AstraZeneca,":[767],"Aveo":[768],"pharmaceuticals,":[769],"Bayer,":[770],"Beigene,":[771],"Blueprint,":[772],"BMS,":[773],"Boeringer":[774],"Ingelheim,":[775],"Celgene,":[776],"Chugai,":[777],"Clovis,":[778],"Sankyo,":[780],"Debiopharm,":[781],"Eisai,":[782],"Eos,":[783],"Exelixis,":[784],"Forma,":[785],"Gamamabs,":[786],"Genentech,":[787],"Gortec,":[788],"GSK,":[789],"H3":[790],"bio,":[791],"Abbvie:":[794],"Funding.":[796],"Varga:Astra":[797],"Zeneca:":[798],"Current":[799,802,835,839],"Employment.":[800],"Ribrag:argenX:":[801],"equity":[803,840],"holder":[804,841],"publicly-traded":[806,843],"company,":[807,844],"Roche/Genentech:":[810],"Consultancy,":[811,838,871,887,902,915,928,943,974,986,1002],"arGEN-X-BVBA:":[822],"BAY1000394":[825],"studies":[826],"MCL:":[828],"Patents":[829],"Royalties;":[831],"Institut":[832],"Employment;":[836],"Epizyme:":[837],"Gilead:":[858,901],"Incyte:":[870],"Pharmamar:":[886],"Honoraria;":[900,929],"MSD:":[914],"Servier:":[927],"Nanostring:":[942],"F.":[955],"Hoffmann-La":[956],"Travel":[970,999],"Expenses;":[971,1000],"Immune":[972],"Design:":[973],"BMS:":[985],"Infinity:":[1001],"committees.":[1013]},"counts_by_year":[],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2020-11-09T00:00:00"}